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Abstract
Background: We have recently shown that radiotherapy may not only be a successful local and regional treatment
but, when combined with MSCs, may also be a novel systemic cancer therapy. This study aimed to investigate the
role of exosomes derived from irradiated MSCs in the delay of tumor growth and metastasis after treatment with
MSC + radiotherapy (RT).
Methods: We have measured tumor growth and metastasis formation, of subcutaneous human melanoma A375
xenografts on NOD/SCID-gamma mice, and the response of tumors to treatment with radiotherapy (2 Gy), mesenchymal
cells (MSC), mesenchymal cells plus radiotherapy, and without any treatment. Using proteomic analysis, we studied the
cargo of the exosomes released by the MSC treated with 2 Gy, compared with the cargo of exosomes released by MSC
without treatment.
Results: The tumor cell loss rates found after treatment with the combination of MSC and RT and for exclusive RT, were:
44.4% % and 12,1%, respectively. Concomitant and adjuvant use of RT and MSC, increased the mice surviving time 22,5%
in this group, with regard to the group of mice treated with exclusive RT and in a 45,3% respect control group. Moreover,
the number of metastatic foci found in the internal organs of the mice treated with MSC + RT was 60% less than the
mice group treated with RT alone. We reasoned that the exosome secreted by the MSC, could be implicated in tumor
growth delay and metastasis control after treatment.
Conclusions: Our results show that exosomes derived form MSCs, combined with radiotherapy, are determinant in
the enhancement of radiation effects observed in the control of metastatic spread of melanoma cells and suggest that
exosome-derived factors could be involved in the bystander, and abscopal effects found after treatment of the tumors
with RT plus MSC. Radiotherapy itself may not be systemic, although it might contribute to a systemic effect when used
in combination with mesenchymal stem cells owing the ability of irradiated MSCs-derived exosomes to increase the
control of tumor growth and metastasis.
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Introduction
Radiotherapy is a critical and inseparable component of
comprehensive cancer treatment and care [1]. It is esti-
mated that about half of cancer patients would benefit
from radiotherapy for treatment of localized disease,
local control, and palliation [2]. The success of RT in
eradicating tumors depends on the total radiation dose
being delivered accurately [3]. However, there are limits
to the RT dose that can be given safely, which are imposed
by the tolerance of the normal tissues surrounding the
tumor [4, 5] and it is clear that the high intrinsic sensiti-
vity of normal tissues to ionizing radiation often precludes
the application of curative radiation doses [6, 7].
Cell membranes are intimately involved in the bio-
chemical events that define cancers, and in particular,
they are intensely involved in cancer metastasis [8]. In
addition, the establishment of metastases also requires a
complex interplay between malignant cells, normal cells,
stroma, mesenchymal cells and extracellular matrix in
their new microenvironments to facilitate invasion of
extracellular matrix and tissue stroma and evade the
defenses of the host [8–10].
Mesenchymal stem cells (MSCs) are found ubiquitously
in many tissues and are not restricted to those of meso-
dermal origin such as bone marrow, adipose, muscle and
bone [11]. MSC-based new therapies could potentially
treat a wide range of conditions, such as cancer, inflamma-
tory and degenerative disorders that have historically chal-
lenged patients and clinicians [12]. Although the use of
MSCs for cancer therapy are considered as a useful tool in
various studies [13], more research is necessary to under-
stand their tumor promoting and suppressing potentials
and to circumvent donor variations [13, 14].
The ability of MSCs to accumulate at tumor sites
makes them extremely attractive for directed cancer
therapy; moreover it has been described that the
tumor-tropism of MSCs increase with radiotherapy [15].
Mesenchymal cells MSCs are recruited by tumors from
both nearby and distant locations.
Cells can secrete ‘molecular machinery’ through sev-
eral types of vesicular carriers that are composed of both
membrane and cytosolic constituents. Cell secreted exo-
somes (30–100 nm extracellular vesicles) play a major
role in intercellular communication due to their ability
to transfer proteins and nucleic acids from one cell to
another [16]. Depending on the originating cell type and
cargo, exosomes may have either immunosuppressive or
immuno-stimulatory effects, which have potential
applications as immuno-therapies for cancer and
auto-immune diseases [17]. In addition, exosomes might
also have tumor-promoting or tumor-suppressor acti-
vities. Very recently, Hoshino and co-workers [18] have
demonstrated that cell-tumor-derived exosomes prepare
a favorable micro-environment at future metastatic sites
and mediate non-random patterns of metastasis. Emerging
evidence shows that exosomes are incipient mediators of
cancer-host crosstalk and are involved in tumor initiation,
growth, invasion and metastasis [8–10]. Tumor-secreting
factors can also increase metastasis by inducing vascular
leakiness, promoting the recruitment of pro-angiogenic im-
mune cells, and influencing organotropism and it has been
shown that tumor-derived exosomes uptaken by
organ-specific cells prepare the pre-metastatic niche and
may also facilitate organ-specific tumor metastatic behavior
[18, 19]. It has also been described that thorax irradiation
could facilitate the spread of surviving tumor cells and thus
tumor recurrence under certain conditions [20], and that
therapy with MSC protects lungs from radiation-induced
injury and reduces the risk of lung metastasis [21].
Developments in understanding of tumor response
and ways to modify it resulting from combination of RT
with pharmaceutical agents to abrogate toxicity, repre-
sent an area of exciting research and development,
which offer potential to improve the therapeutic ratio
[3]. We have recently shown that the combination of
MSC cell therapy plus radiotherapy in melanoma
tumor-xenografts implanted in NOD/SCID-gamma--
mice, significantly reduced the size of the established tu-
mors, both in the primary-directly irradiated tumor as
well as in the distant non-irradiated tumor [22].
Taking into account these antecedents and our previ-
ous studies [22, 23], in the current study we aimed to
elucidate the mechanism by which mesenchymal cells
counteract the pro-tumor and pre-metastatic actions of
tumor cells through isolation and identification of key
components in exosomes derived from irradiated MSCs.
“Radiotherapy may not only be a successful local and re-
gional treatment but, when combined with MSCs, may
also be a novel systemic cancer therapy”.
Material and methods
Cell lines and culture
Umbilical-cord stromal stem cells (MSCs) were prepared
and cultured as previously described [24, 25]. Tumor cell
lines A375, G361 and MCF7 were cultured as previously
described [23, 26]. All the cells were kept in a humidified
incubator with 5% CO2 at 37 °C. The FBS utilized to pre-
pare conditioned medium was depleted of bovine exosomes
as described elsewhere [27] by ultracentrifugation of 50%
(v/v) diluted FBS on DMEM at 100,000 ×g for 16 h at 4 °C.
All the cell lines were routinely tested for mycoplasma fol-
lowing the manufacturer’s instructions and were found to
be negative (e-MycoTM plus Mycoplasma PCR Detection
Kit, Intron Biotechnology, Korea).
Xenografts of A375, G361 and MCF7 cell lines
We implanted 1·106 cells from the human cancer line G361,
A375 or MCF7 into 7/9-week-old NOD/SCID-gamma
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(NSG) mice following the same procedure we used in our
previous study [22]. Four groups of eight mice were treated
with radiotherapy, MSC therapy, MSC therapy before radio-
therapy, or left untreated (control). When necessary, mice
were anesthesized with isoflurane or ketamine/medetomi-
dine (41 mg and 0,5 mg per kg of animal weight, respect-
ively) with reversal by atipamezole (1,2 mg/kg animal
weight) to minimize anesthesia recovery duration. The total
treatment duration was at least four weeks. After the final
dose, we followed tumor size and mice weight and welfare
for an additional 6–10 days before ending the experiments.
Mice groups to study the A375 spontaneous metastatic
process.
Radiotherapy group
One group (8 mice) with a tumor on each hind leg was
anesthetized with ketamine/medetomidine and only one
of the tumors was treated with a dose of 2 Gy. Ionizing
radiation was delivered by X-Ray TUBE (YXLON, model
Y, Tu 320-D03) as described previously [22]. The treat-
ment was repeated once-a-week for a total of two weeks.
MSC therapy groups
Two groups (8 mice in each group) with tumors larger
than 60 mm3 were treated with an intraperitoneal ad-
ministration of 106 MSC once-a-week for 2 successive
weeks. The day after each cellular treatment, one of the
groups (8 mice) was randomly selected to have one of
their tumors irradiated. The other group was monitored
and treated repeatedly with injections of MSC every
week for 2 weeks.
Control group
One group (8 mice) with tumors on each leg was han-
dled in exactly the same way as the irradiated and MSC
injected mice, although the group did not receive either
radiation or MSC therapy.
Biodistribution of MSCs on tumor-bearing mice
We labelled MSCs with BrdU or with luciferase to fol-
low their biodistribution when injected intratumorally or
intraperitoneally. To label MSCs with BrdU we treated
exponentially growing cells with 10 μM BrdU for 24 h
before using them. By labelling the injected MSCs with
BrdU we were able to identify them later on formalin-
fixed paraffin-embedded sections of the tumors 24 h
after the injection.
Tumor growth measures and calculations
We monitored the tumor sizes every 2–3 days and mea-
sured two perpendicular diameters from each tumor to
calculate tumor volume. The mathematical model ap-
plied for the analysis of this set of data obtained in our
experimental therapeutic studies to measure the growth
of tumors as a function of time, is the exponential
growth. Under the conditions of the experiments, the
logarithm of tumor volume increase linearly with time.
For more details see our previous paper [22].
Using the individual tumor growth kinetics equation
fitted for each one of the tumors, we calculated the ne-
cessary time for tumors to reach a volume of 2.00 ml
(time to tumor growth) in a similar way to the concept
previously described [28, 29], the values corresponding
to each group allow us to assess the treatment efficiency
in terms of increase of survival time in each one of the
therapeutics groups studied, compared with the control
group. Furthermore, from the fit of the experimental
data to for the growth of tumors as a function of time,
to an exponential equation we can obtain the value of
the slope and, using this, the values for the duplication
time (TD). The Extra sum-of-squares F-Test for com-
paring fits of different curves was made [22] using
GraphPad Software.
Histopathological and immuno-histochemical studies
At the end of the experiments, we recovered the xeno-
grafts from each study group, the complete thorax and the
abdominal and pelvic organs and fixed in 10% buffered
formalin for 48 h. Paraffin-embedded 4 μm sections were
dewaxed, hydrated, and stained with hematoxylin-eosin.
We determined the mitotic index, the necrotic areas and
apoptotic cells observed outside the necrotic fields and a
complete and protocolized macroscopic and microscopic
study of the pelvic, abdominal and thoracic organs was
done to assess possible metastasis. We studied one histo-
logical section of heart, mediastinum, spleen, pancreas; a
longitudinal section of kidneys, the genital tract, a seg-
ment of the large intestine, and lymph nodes found plus
all the lung lobules and five longitudinal liver sections. It
was considered as different metastatic foci if there were
interposed healthy parenchyma between groups of more
than 10 neoplastic cells. For further details on Exosomes
purification, characterization and analysis, proteomic
analysis, and statistical analysis see Additional file 1.
Results
Previously we have shown that MSCs increased their
tumor suppressor activity when they are activated with
radiotherapy. In the current study we wondered if this
anti-tumor action could also be relevant in decreasing
metastatic spread. To assess this effect, we implanted
three different tumor cell lines, G361, A375 and MCF7,
in both flanks of NOD/SCID mice to produce bilateral
xenografts. Our results demonstrate that the A375
human skin-melanoma cancer cell line, when implanted
as xenografts, in the NOD/SCID-gamma mice growth
faster than G361 and MCF-7 cell line xenografts more-
over, A375 xenografts are able to spread from its initial
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location to produce metastases in the internal organs of
the mice, whereas, in our model, the cell lines G361 and
MCF7 lack this potentiality (Additional file 1: Table S1).
60 out of the 97 mice bearing A375 xenografts showed
metastatic spread (Fig. 1a). Of these mice, 59 of the 60
(98.3%) showed lung poli-metastasis, the mean number
of metastatic foci on lungs being 14.2 ± 1.8. After that,
the organs more frequently invaded by the tumor cells
are the liver (33/60; 55.0%); the kidney (20/60; 33.3%)
and the lymph nodes (4/60; 6.7%). The data suggest that
the lung is the initial target of metastatic dissemination
and after this step, and more slowly, tumor cells may
reach the liver and/or kidney. Thus, for the rest of the
study we used A375 cell line as model to evaluate the ef-
fect of radiotherapy, mesenchymal cell and MSC plus
radiotherapy on the tumors (irradiated and bystander)
and on the metastatic spread process.
Biodistribution of MSC injected or infused in mice
To study the movement of cells inside the A375 xeno-
grafts we injected MSCs labeled with BrdU (106 cells)
intratumorally and performed the histological study 24 h
post-injection (Fig. 2a). The histological study shows that
injected (brown) MSCs were present inside the tumor tis-
sue and that they localized along longitudinal trajectories
whose tracing could be associated with the existence of
neo-formed vessels within the xenografts. In fact the shape
of the MSCs resembles that which is characteristic of
normal pericytes as has been previously described: Once
inside the tumor MSCs are incorporated into their stroma
and could remain, as pericytes, in the environment of the
vessel walls that nourish the neoplastic process [30].
We also studied the biodistribution of MSCs, genetically
modified to express the luciferase gene on tumor-bearing
NSG mice. Figure 2b shows images (IVIS-Lumina II) cor-
responding to mice with A375 tumor xenografts placed
on the upper part of both hind legs. We treated the tumor
on the right flank of the mice with RT (2 Gy). Right after
the MSC injection, the luminescence occupies the abdo-
minal region. At day 1 the pattern of cell distribution is
different and suggests that the highest cell density is found
in the central region of the mouse body and in its
pulmonary and circulatory systems. At day 2, apart from
the central focus, there is another region with intense bio-
luminescence that seems to fit to the border of the irradi-
ated tumor. This pattern is maintained 5 days after the
injection of cells.
MSC combined with RT reduces the number of observed
metastasis.
To further evaluate the anti-metastatic potential of MSCs
combined with RT, we have carried out experiments to
follow tumor-volume growth kinetics during a time-
course of only 14 days. Reducing the duration of the ex-
periment reduced the probability of a massive metastatic
spread of tumor cells in almost all mice included in the
study, regardless of the treatment, and allowed us to assess
the differences among the groups. All the growth curves
obtained either in Control as in MSC, RT and RT +MSC
groups has been plotted in Fig. 3.
We made one key assumption in the model: Tumor
growth rate is constant in the interval of time between
the start of data acquisition and the end of the experi-
ment, and treated tumors grow slower than the control
Fig. 1 a Distribution of A375 xenografts’ micro-metastasis in the internal organs of the tumor-bearing NOD/SCID-gamma mice. Results are
expressed as mean value ± standard error of mean. b Representative photomicrographs of H&E from lungs, liver, kidney and intravascular micro-
metastasis (black arrow)
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tumors because their doubling times are longer. Com-
paring the tumor response curves in the mice treated
with RT, MSC, MSC + RT or without any treatment,
(Fig. 4a), we have observed an improved tumor response
in the group treated with MSC + RT (green curve) com-
pared to the groups of mice treated with RT (red curve,
P < 0.0001) or with MSCs (blue curve, P < 0.0001), exclu-
sively. We have shown that this mathematical model
properly described the growth A375 tumors, until more
than 30 days (Additional file 2: Figure S1).
The calculated values of duplication time (days) are
the following: Control = 4,21; MSC = 4,93; RT: 4,79; RT
+MSC = 7,57, Bys-RT = 4,48 and Bys-RT +MSC = 4,80.
Using these values, we have calculated the cell-loss rate
(CL) that can be attributed to each treatment [22, 31]. The
CL for RT +MSC was: 0,44 and for RT alone 0,12. Accor-
ding to this concept we can state that radiotherapy inhi-
bited tumor growth with a cell loss rate of 12.0% per day
compared to tumor growth in the control group. This effect
was enhanced by the addition of MSCs to the radiotherapy,
with cell lost rate of 44,4% per day, leading to a
mesenchymal enhancement ratio of MSC-ER = 3,7, whilst
MSCs alone inhibited tumor growth with a cell loss rate of
14,5%. Assuming that the effects for each of the treatments
(RT and MSC) are independent [32], we have calculated
that the expected value (E) for the surviving fraction after
the treatment with RT +MSC is: E = 0,75. On the other
hand, the observed value for the surviving fraction after RT
+MSC is O = 0,44. Using both data we have calculated the
ratio O/E = 0.59, which is a strong indicator of the synergis-
tic effect [32] between RT and MSC when they are applied
together for tumor treatment in this model. These results
demonstrate the potentiation of the bystander effect by the
MSCs used together with radiotherapy.
To get an approach to the survival of the mice in each
group, we have calculated the time-to-tumor growth
(T-t-G), a theoretical tumor end-point-time for tumor
growth [28], defined in this case as the time necessary for
each tumor to reach the volume of 2,00 ml. The differ-
ences between the times necessary for the tumors from
each group to reach 2,00 ml among the groups are statisti-
cally significant (Fig. 4b, P < 0.0001) and specifically the
Fig. 2 Biodistribution of MSC on tumor-bearing mice injected intratumorally or intraperitoneally. a Representative photomicrographs of A375
xenografts 24 after BrdU-labelled MSCs (brown) intratumoral injection. b Biodistribution of luciferase-labelled MSCs injected intraperitoneally on
tumor-bearing NSG mice after receiving radiotherapy (right flank). The images were obtained at 0, 1, 2 and 5 days after injecting
(intraperitoneally) 10 luciferase-expressing MSCs. Luciferin was injected 5 min before the images are obtained
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use of MSC together with RT increase the time-to-tumor
growth of mice included in the therapeutic groups, with
respect to the mice included in the control group. Values
of time-to-tumor growth have been plotted in Fig. 4b and,
interestingly, the combined treatment RT +MSC pro-
duces a clear enhancement of the radiotherapy efficacy
measured as an increase in this parameter.
Our results demonstrate that the combined treatment
with RT +MSC increases the surviving time of the mice
included in this group by 5 days (22%) compared to the
group of mice treated exclusively with RT and more than
11 days (60%) compared to the control group. Of inter-
est is the bystander effect of the radiotherapy on the
tumor of the contra-lateral side, which by itself led to an
inhibition of tumor growth corresponding increase of
1 day in the T-t-G. Tumors from the non-irradiated
flank, thus exposed to the bystander effect after RT +
MSC treatment, showed a further inhibition of tumor
growth increase in T-t-G of 3,6 days compared to the
tumor growth under control conditions.
Next, we analyzed the amount of metastasis foci
present in each of the mice included in the different
groups. Metastases were microscopically identified
and counted to calculate their frequency. Figure 5a
illustrate the difference in size between A375 xeno-
grafts respect to control and MSC + RT groups at the
end of the experiment. To further quantify the inhibition
of tumor foci by MSCs the number of metastasis pooled
Fig. 3 Kinetics of individual tumor growth and its treatment response to (a) Control, (b) MSC, (c) RT, (d) MSC + RT, (e) bystander tumor after RT
and (f) bystander tumor after MSC + RT. Black points at the of the extrapolated curves represents the time to tumor growth (T-t-G) values. The
different colors on the graphs represent a different animal within each group. Full dots represent the treated tumor (when applicable) and open
dots represent its contralateral tumor
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in each cohort of mice was expressed as a fraction of its
respective control group. We compared: control vs. MSC
and RT vs. RT +MSC. These results are summarized in
Fig. 5b. The analysis of Fig. 5b suggest that infusion of
MSCs accounted for a reduction of approximately 62% (P
= 0.0020) if we compare mice treated only with RT with
the group treated with RT +MSC, indicating that the
combination RT +MSCs produces an important reduction
in the metastatic potential of the human melanoma A375
xenografts. Figure 5c-f exemplifies the amount of micro-
metastasis on lungs of mice from control, MSC, RT and
MSC + RT groups.
Fig. 4 a Mean values of the growth kinetic curves of the xenotumors infused on NSG mice. Different curves hat different slopes (P < 0,0001) and
the differences between RT and RT +MSC curves are also significant (P < 0,0001). b Extrapolated values of the time to tumor growth until a
volume of 2,00 ml. The treated tumors growth slowly than un-treated and bystander tumors. The mean value of tumors with RT +MSC is
significantly longer than the T-t-G in the group treated with RT alone
Fig. 5 Histopathological study of the internal organs of the tumor-bearing mice treated for only 15–17 days, (a) Representative panoramic
images of A375 human melanoma xenografts from Control and MSC + RT. b Comparisons between the metastasis incidence of Control vs. MSC
and RT vs. MSC + RT. MSC treatment alone had no effect on the metastasis incidence index. The combined treatment of MSC + RT diminished the
early spread of metastases produced by the A375 xenograft. Representative photomicrographs of H&E lung micro-metastases from (c) Control, (d)
MSC, (e) RT and (f) MSC + RT treatment groups
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Exosomes secreted from MSCs are quantitatively,
functionally and qualitatively different from the
exosomes secreted from MSCs*
Exosomes (Exo) and microvesicles (MV) secreted by
mesenchymal cells, from both inactivated MSCs and ac-
tivated MSCs*, have been quantified measuring the
amount of protein present in each of the fractions from
the sequential centrifugation method used to separate
MV and Exo. Typical images of the Exo and MV from
MSCs, obtained by transmission electronic microscopy,
are summarized in Fig. 6a. The values of protein concen-
tration in the paired experiment designed for this pur-
pose, suggest that the treatment of MSCs with 2 Gy of
low-LET ionizing radiation dose produces the activation
of the irradiated cells, increasing the secretion of
proteins to the culture media by the stimulated cells
(Fig. 6b): MSC* = 0.251 ± 0.002 μg/ml vs. MSC = 0.214 ±
0.004 μg/ml, P = < 0.0001. The differences between pro-
teins in MV and Exo from MSC and MSC* are statisti-
cally significant (Fig. 6b): Exo: MSC = 0.091 ± 0.002 μg/
ml vs. MSC* = 0.140 ± 0.001 μg/ml, P < 0.0001 and MV:
MSC = 0.123 ± 0.003 μg/ml vs. MSC* = 0.111 ± 0.001 μg/
ml, P = 0.0002 (Fig. 6b). Our data demonstrate that the
exosomes secretion in MSCs* increased 1.5 fold times
respect to MSCs.
Exosomes and proteins secreted by MSCs might be
involved in the antitumoral effects observed
Exosomes are pivotal in facilitating intercellular commu-
nication [33]. We wonder if the exosomes produced by
MSCs and MSC*, can modulate the growth of tumor
cells by affecting major cellular pathways that lead to the
cell death of the tumor cells, which could be the protein
“cargo” contained in these exosomes [16] and whether it
is possible to identify differences between the tumor-
suppressor activity of exosomes obtained from MSCs
and from activated MSCs*.
Figure 6d-f summarizes the results of a cell survival
assay [34] adapted to measure G361 and A375 survival
fraction. We compared the survival fractions of tumor
cells treated with MSC or MSC* conditioned medium
(Fig. 6d-e) and then compared the effect of MSC* exo-
somes on A375 cells (Fig. 6f ). The potency index is de-
fined as the relation between the estimated surviving
fraction from MSC*-exosomes and the MSC-exosome
treated cells.
MSC* exosomes reduce the cell survival of A375 cells
(P < 0.0001) as the unfractioned conditioned media of
MSC* does. This indicates that the activation of MSCs
with 2 Gy increases its tumor-suppressor effect. As we
found a dramatic cytoreductor effect of MSC* exosomes
on the tumor cells, we have examined the protein con-
tent in these nanosized oraganelles. The results of these
experiments are in Fig. 7 and in Additional file 1.
Exosome function enrichment
To further characterize the functionality of the exosome
content from MSC and MSC* we have used a bioinfor-
matics tool aimed to identify the signaling pathways in-
volved in different key cellular process. Significant
biological process terms from REVIGO were studied in
detail (Fig. 7). 15 common terms were obtained between
MSC and MSC* results, 20 terms were exclusively
enriched in MSC and 41 from MSC* (p-value < 0.01 or
log10 p-value<− 2), as shown in detail in Additional file 1.
According the uniqueness values, dispensability values
and p-values, common GO terms between MSC and
MSC* are related to calcium-independent cell-matrix
adhesion, transport mediated by vesicles, platelet degranu-
lation and activation and cardiovascular development (see
details in Fig. 7). However, enriched terms from MSC exo-
somes are correlated to wound healing, coagulation,
hemostasis and regulation of immune response (displayed
in Fig. 7). Interestingly, MSC* analysis generated the most
prominent and diverse terms in relation to the control of
tumor growth, in particular the negative regulation of re-
sponse to stimulus, localization of cell, leukocyte cell-cell
adhesion and positive regulation of cell death (shown in
Additional file 1).
Discussion
In this paper, we present a set of preclinical therapeutic
data in which we combine RT with MSC therapy. We
have demonstrated that tumor cell loss induced after
treatment with radiotherapy increases with the combin-
ation of RT and MSCs, reaching 51.4% per day when
compared to RT alone, which was only 25.8% per day
with an MSC enhancement ratio of around 2 (Additional
file 2: Figure S1). These values indicate that the combin-
ation of MSC + RTs produces a synergic effect. Further-
more, we have calculated the differences in the time
necessary to reach 2,00 ml of tumor volume from the
different groups (Fig. 4b). Tumors treated with RT alone
would need 24.4 days to reach this volume and mice
treated with the combination of MSC + RT would need
29.8 days. Our results demonstrate that the concomitant
and adjuvant use of RT and MSCs could represent an in-
crease of the surviving time of the mice included in this
group of around 22%, compared to the group of mice
treated exclusively with RT. Moreover, the number of
metastatic foci found in the internal organs of the mice
treated with MSC + RTs was a 60% less than in the
group of mice treated with RT alone.
The paracrine effect of MSC was first described almost
two decades ago by Haynesworth and co-workers [35].
Extracellular vesicles such as exosomes are naturally
released from MSCs and in our model might be respon-
sible for the survival reduction of tumor cells in vitro.
Understanding the fundamental biology underlying
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mesenchymal stem cell and tumor interactions has the
potential to increase our knowledge of cancer initiation
and progression, and also lead to novel therapeutics for
cancer. Exosomes derived from mesenchymal stem cells
seems to be key players at this respect. Due to their
properties, MSCs may be qualified as a therapeutic tool
to treat radiation-induced tissue damage [36]. Numerous
studies have shown that administered either intraperito-
neally or intravenously MSCs efficiently home onto
tumors and metastases [37, 38]. Exosomes secreted by
MSCs have been shown to contain antiapoptotic miR-
NAs, to promote epithelial and endothelial wound hea-
ling and angiogenesis, and to contain growth factor
receptor mRNAs, known to promote wound healing and
Fig. 6 a Morphologic characterization of the extracellular vesicles released by MSC and MSC* precipitated by differential ultra-centrifugation. b
Total protein concentration on the extracellular vesicles released by MSC and MSC*. c Protein concentration on the microvesicles and exosomes
from MSC and MSC*. MSC or MSC* unfractioned conditioned medium reduced the surviving fractions of (d) A375 and (e) G361 cells. f Comparison
between unfractioned conditioned medium from MSC and MSC* and of its exosomes on the A375 cell line. MSC conditioned medium (blue points)
has been considered as the control as there is any statistical differences between MSC and growth media controls (data not shown). Differences are
statistically significant between conditioned medium (P < 0.05) and exosomes (green points, P < 0.0001) from MSC and MSC*
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protect the intestines from experimental necrotizing en-
terocolitis [39]. We have demonstrated in vitro, that exo-
somes separated from the culture medium of MSCs are
quantitatively, functionally and qualitatively different
from the exosomes obtained from MSC activated cells.
When we analyzed the exosome “cargo”, before and after
activation with RT, we have found important differences
in the proteomic content between the samples.
Our results (Fig. 7 and Additional file 1) show that there
are qualitative differences between the proteins contained
in the exosomes obtained from MSCs and MSCs*.
According with the GO terms obtained through a
hypergeometric analysis, we found a different enrichment
of terms between MSC and MSC* exosomes in different
biological processes as well as in the number of pathways
affected. Thus, whereas the numbers of highly significant
common GO terms and MSC terms are in consonance,
MSC* results generated a large variety and number of
pathways altered, and it demonstrate the profound meta-
bolic alteration that have undergone these exosomes.
Consequently, the results show that common GO
terms and MSC terms are similar and related with exo-
some functions. Therefore, as shown in Additional file 1
the distribution of clusters is analogous and clusters rep-
resentatives are associated with transport mediated by
vesicles, coagulation (through platelet roles), develop-
ment processes or immune response. On the contrary,
as shown in Fig. 7, and Additional file 1, MSC* enriched
terms are more disperse, having different and intercon-
nected clusters with a complex biological background.
Among the more representative clusters we highlight
leukocyte cell-cell adhesion, cell localization, and nega-
tive regulation of responses to stimulus and cell death.
Some of these proteins are key components of cell-cell
or cell-matrix adhesion (Additional file 1) and includes
annexin and integrins such as ANXA1, ANAX2, ITGB1,
ITGA3, FN1, CTNNB1, APOH which interplay may ac-
tivate exosome and leukocyte adhesion to tumor cells to
limit tumor growth. The presence of annexin is very sig-
nificant only in the exosomes released from MSCs*. The
prototype member of this family, ANXA1, has been
widely recognized as an anti-inflammatory mediator af-
fecting migration and cellular responses of various cell
types of the innate immune system [40]. Moreover,
ANXA1 mRNA was tremendously up-regulated follo-
wing MSCs irradiation (Additional file 2: Figure S2).
Interestingly some key biological aspects of ANXA1
(potential tumor suppressor gene, ability to modulate
tumor cells apoptosis induced by ionizing radiation and
radiotherapeutic efficacy) deserve future studies to fully
elucidate its role in the therapeutic effect of exosome
derived from irradiated MSCs.
The therapeutic efficacy of transplanted MSCs actu-
ally seems to be independent of the physical proxim-
ity of the transplanted cells to damaged tissue. The
number of MSCs that engraft into injured tissues may
not be sufficient to account for their robust overall
protective effects. Exosomes secreted by MSCs have
been shown to contain anti-apoptotic miRNAs, to
promote epithelial and endothelial wound healing and
angiogenesis, and to contain growth factor receptor
mRNAs, known to promote wound healing. Consid-
ered to be a vectorized signaling system, we believe
that the exosomes released from MSCs seem to bind
to specific membrane micro-domains on tumor cells,
which widen the radiotherapy action, by stimulating
tumor cell death thus increasing the sensitivity of
cells to radiation and promoting the systemic effects.
This hypothesis provides a rationale for the thera-
peutic efficacy of MSCs and their secreted exosomes
Fig. 7 Cluster analysis of the Gene Ontology (GO) Biological Process terms from the common and unique proteins identified in the exosomes of
MSC and MSC*. Terms, represented as circles, are collapsed into clusters according to semantic similarities. The labels on the graphics represent
the most unique terms. Circle colors reflect the p-values and circle sizes the number of identified proteins within the GO term. a MSC exosomesc.
b Shared exosomes between MSC and irradiated MSC (MSC*). c MSC* exosomes
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in a wide spectrum of diseases, and also rationalizes
the additional use of MSC exosomes as an adjuvant
to support and complement other therapeutic moda-
lities [11].
Conclusions
Our results show that exosomes derived from irradiated
MSCs may be a determinant factor in the enhancement
of radiation effects leading to increased metastasis con-
trol. Radiotherapy itself may not be systemic, although it
might contribute to a systemic effect when used in com-
bination with mesenchymal stem cells.
Additional files
Additional file 1: Significant biological process terms from REVIGO
(Reduce + visualize gene ontology). (XLS 51 kb)
Additional file 2: Figure S1. (a) Tumor growth kinetics and response to
radiotherapy administered twice-a-week alone or in combination with
simultaneous MSC* injection. The combination of radiotherapy and MSC*
reduced tumor growth rate more than radiotherapy alone did. (b) Calcu-
lated time to tumor growth (T-t-G) for each group. As a result of the re-
duction on tumor growth kinetics, tumors from the group receiving the
combination of RT + MSC* would need more days to reach 2,0 ml. 3.
What do the authors mean by MSC* + RT in Fig. S1. The notation (MSC*
+ RT) means: MSC*: in vitro activated (2 Gy of low-LET (lineal energy
transfer) radiation) mesenchymal cells were administered intraperitone-
ally; RT: 2 h after MSC* injection tumors were treated locally with radio-
therapy (RT, 2Gy). This combined treatment was repeated every 4 days
during a total of 24 days. Figure S2. mRNA expression of TRAIL, DKK3
and ANXA1 by MSCs 24 and 48 h after receiving 2 Gy of radiation. The
overexpression of TRAIL and DKK3 is consistent with our previous study
[22], the ANXA1 overexpression is consistent with the presence of the
protein form inside the MSC* exosomes. (ZIP 1301 kb)
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